Company: TVRD
Filing Date: 2025-02-14
Form Type: S-4/A
Source: 0001104659-25-013053
Chunk: 939

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: S-4/A
Chunk 939
---
 financial position of the Company as of September 30, 2024, and results of operations and cash flows for all periods presented. The interim results presented are not necessarily indicative of results that can be expected for the full year ending December 31, 2024.

#### 2.   Summary of Significant Accounting Policies
Other than policies noted below, there have been no significant changes from the significant accounting policies and estimates disclosed in Note 2 of the “Notes to Financial Statements” in the Company’s audited annual financial statements included elsewhere in this proxy statement/prospectus.

#### Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and expenses as of and during the reporting period. The Company bases estimates and assumptions on historical experience when available and on various factors that it believes to be reasonable under the circumstances. The Company assesses estimates on an ongoing basis; however, actual results could materially differ from those estimates.

<div align='center'>F-120</div>

TABLE OF CONTENTS

Tvardi Therapeutics, Inc. Notes to CONDENSED Financial Statements
(Unaudited) Significant estimates and assumptions reflected within these condensed financial statements include, but are not limited to, prepaid and accrued research and development expenses, including those related to contract research organizations, or CROs, contract development manufacturing organizations, or CDMOs, and other third-party vendors, and the valuation of the Company’s common stock and stock- based awards. Changes in estimates are recorded in the period in which they become known. Concentration of Credit Risk and of Significant Suppliers The Company’s cash and cash equivalents represent potential concentrations of credit risk. The Company deposits its cash and cash equivalents in financial institutions in amounts that may exceed federally insured limits, has not experienced any losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The following table presents information about the Company’s significant suppliers:

| ​        | ​ | ​ | For the Nine Months EndedSeptember 30, |   |     |   |   |   |      |   |     |   | ​ | ​ |   As ofSeptember 30, |   |     |   | ​ | ​ | As ofDecember 31, |   |     |   | ​ |
| ​        | ​ | ​ |                                   2024 |   |     |   | ​ | ​ | 2023 |